Suppr超能文献

急性髓系白血病的免疫疗法与化疗:白血病患者缓解期淋巴细胞对PHA、同种异体淋巴细胞及白血病成髓细胞的反应

Immunotherapy versus chemotherapy of acute myeloid leukemia: response to PHA, allogeneic lymphocytes, and leukemic myeloblasts of remission lymphocytes from leukemia patients.

作者信息

Reizenstein P, Ogier C, Sjögren A M

出版信息

Recent Results Cancer Res. 1980;75:29-36. doi: 10.1007/978-3-642-81491-4_5.

Abstract

Lymphocytes were studied from 51 patients with acute myeloid leukemia (AML) in remission given chemotherapy (CT) maintenance alone or given chemoimmunotherapy (CIT) with BCG and viable allogeneic leukemic cells. CT lymphocytes reacted significantly more to PHA (P less than 0.05) if taken later than 100 days after remission than if taken earlier. CIT lymphocytes reacted less. Thus, the late CT lymphocytes reacted significantly more to nonspecific stimulators (PHA and allogeneic lymphocytes, P less than 0.01) than did late CIT lymphocytes or control lymphocytes. In consequence, the ratio of reactions to specific (leukemic myeloblasts) over nonspecific stimulators was significantly higher in CIT (P less than 0.01) than in CT lymphocytes. Results may indicate nonspecific immunostimulation during CT, and also some relative specific sensitization to allogeneic myeloblasts during CIT.

摘要

对51例急性髓系白血病(AML)缓解期患者的淋巴细胞进行了研究,这些患者单独接受化疗(CT)维持治疗,或接受卡介苗(BCG)和有活力的异基因白血病细胞的化学免疫疗法(CIT)。如果缓解后100天以后采集CT淋巴细胞,其对PHA的反应显著高于缓解后100天以内采集的淋巴细胞(P<0.05)。CIT淋巴细胞的反应较弱。因此,晚期CT淋巴细胞对非特异性刺激物(PHA和异基因淋巴细胞,P<0.01)的反应显著高于晚期CIT淋巴细胞或对照淋巴细胞。结果表明,CIT中对特异性刺激物(白血病成髓细胞)与非特异性刺激物反应的比值显著高于CT淋巴细胞(P<0.01)。结果可能表明CT期间存在非特异性免疫刺激,以及CIT期间对异基因成髓细胞存在一定的相对特异性致敏。

相似文献

6
Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.用于急性髓细胞白血病维持治疗的化疗免疫疗法。
Cancer. 1976 Oct;38(4):1581-6. doi: 10.1002/1097-0142(197610)38:4<1581::aid-cncr2820380423>3.0.co;2-y.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验